Compare Davita Inc (DVA) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Nutanix Inc — how do they compare? Davita Inc trades at $179.26 (market cap $11.38B), while Nutanix Inc trades at $64.23 (market cap $17.39B). The key difference: Nutanix Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| DVA | NTNX | |
|---|---|---|
Market Cap | $11.38B | $17.39B |
Sector | Health | Technology |
52-Week High | $240.96 | $81.12 |
52-Week Low | $103.87 | $34.41 |
Enterprise Value | $24.10B | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Nutanix (NTNX) trades at $63.74, down 1.12% today, showing strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock maintains a bullish technical outlook with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent institutional buying activity and positive analyst sentiment (62.5% buy ratings) reflect confidence in the hybrid multicloud platform's growth trajectory.
Outlook remains positive with Q4 earnings expected to beat consensus, though supply chain constraints pose near-term risks. The company's expanding profit margins and VMware migration opportunities provide upside potential, but elevated valuation metrics (P/E 67.71) require continued execution. Investors should monitor Q2 2026 earnings results due August 26th for confirmation of growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
